RxDoctor Payments Data

Benjamin Ringger, MD

Dermatology · Coeur D Alene, IDNPI 1013170125

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 36.1% of the total.

$2,537in general payments, 2019–2025

Across 145 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$915
  • Novartis$427
  • UCB, Inc.$253
  • Johnson & Johnson$248
  • Regeneron Healthcare Solutions, Inc.$199
  • Sanofi$99
  • plus $396 from 12 others

What the payments were for

  • Food & beverage$2,46497%
  • Education$733%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,537 in reported general payments places this provider in the 55th percentile of 52 dermatology providers in Idaho.

See all dermatology providers in Idaho

Medicare billing

Part B allowed, 2024
$908,950
Medicare patients
2,433
Services billed
7,716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$229,448
Taltz AutoinjectorIxekizumab20$139,021
OtezlaApremilast14$67,778
Dupixent SyringeDupilumab12$44,636
Fluorouracil88$8,654
Clobetasol Propionate154$6,210
Mycophenolate Mofetil28$4,819
Doxycycline Hyclate148$4,659
Minocycline Hcl14$2,811
Triamcinolone Acetonide169$2,311
Ketoconazole102$1,485
Metronidazole33$1,359
Tretinoin11$1,236
Hydroxychloroquine Sulfate17$1,136
ValacyclovirValacyclovir Hcl29$1,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$37$67,77814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 52 dermatology providers in Idaho.

Other dermatology in Coeur D Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →